login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock News
USA
- NASDAQ:KZIA -
US48669G3039
-
ADR
7.66
USD
+0.27 (+3.65%)
Last: 11/11/2025, 8:21:17 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KZIA Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: Benzinga
- Mentions:
AZTR
SNTI
ADAP
CODX
...
12 Health Care Stocks Moving In Monday's After-Market Session
16 days ago - By: Kazia Therapeutics Limited
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
a month ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
a month ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
2 months ago - By: Benzinga
- Mentions:
GRI
PRPH
GLMD
COSM
...
12 Health Care Stocks Moving In Thursday's After-Market Session
3 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
2 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
4 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
8 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
9 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
10 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
10 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
10 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
11 months ago - By: Yahoo Finance
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
11 months ago - By: Kazia Therapeutics Limited
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Please enable JavaScript to continue using this application.